We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+7.88%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$172M
Cap. Flow %
141.55%
Top 10 Hldgs %
95.3%
Holding
14
New
14
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$23.4M
2
LOXO
Loxo Oncology, Inc
LOXO
+$19.1M
3
CTMX icon
CytomX Therapeutics
CTMX
+$16.6M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$15.4M
5
PVLA
Palvella Therapeutics
PVLA
+$11.7M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$28.5M 23.48%
+1,250,914
New +$23.4M
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
$22M 18.14%
+126,812
New +$19.1M
CTMX icon
3
CytomX Therapeutics
CTMX
$754M
$14.9M 12.25%
+649,763
New +$16.6M
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$14.1M 11.59%
+401,580
New +$15.4M
PVLA
5
Palvella Therapeutics
PVLA
$2.27B
$10M 8.26%
+24,689
New +$11.7M
FATE icon
6
Fate Therapeutics
FATE
$326M
$6.58M 5.43%
+580,229
New +$6.39M
SPRO icon
7
Spero Therapeutics
SPRO
$73M
$6.11M 5.04%
+416,691
New +$5.33M
LKFT
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$6.09M 5.02%
+66,050
New +$6.41M
AUTL
9
Autolus Therapeutics
AUTL
$562M
$4.02M 3.31%
+150,000
New +$3.96M
CLLS
10
Cellectis
CLLS
$285M
$3.36M 2.77%
+118,873
New +$3.54M
SYBX
11
DELISTED
Synlogic
SYBX
$3.02M 2.49%
+20,453
New +$3.29M
XBI icon
12
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$1.36M 1.12%
+600,000
New +$55.1M
FPRX
13
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.02M 0.85%
+64,881
New +$1.13M
MOR
14
DELISTED
MorphoSys AG American Depositary Shares
MOR
$303K 0.25%
+10,000
New +$275K

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q2 2018 Portfolio in Review

Q2 2018 is the first quarter with a 13F filing on record for Aquilo Capital Management, which disclosed 14 positions worth $121M. Its ten largest holdings account for 95% of the portfolio.

Its largest position is Merus: 1,250,914 shares worth $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets.

  • Aquilo Capital Management's largest Q2 2018 buy was Merus: 1,250,914 shares worth $28.5M.
  • Aquilo Capital Management's ten largest holdings make up 95% of its $121M portfolio in Q2 2018.
  • Aquilo Capital Management disclosed 14 positions in Q2 2018, its first 13F filing on record.

Based on Aquilo Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.